Additional Information

Description

Sprycel (Dasatinib 50 mg) Tablets is a tyrosine kinase inhibitor (TKI) indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL). It functions by inhibiting BCR-ABL kinase and Src family kinases, disrupting leukemic cell proliferation and survival. This targeted inhibition effectively slows disease progression and improves hematologic and cytogenetic responses in affected patients.

Sprycel is available as 50 mg oral tablets, with each bottle containing 60 tablets. The standard dosage for chronic-phase Ph+ CML is 100 mg once daily, while for accelerated-phase or blast-phase CML and Ph+ ALL, the recommended dose is 140 mg once daily. Tablets should be taken with or without food, swallowed whole, and not crushed or split. Dose adjustments may be required in patients with severe adverse effects, renal or hepatic impairment, or drug interactions.

Common adverse effects include myelosuppression, pleural effusion, fluid retention, diarrhea, fatigue, and rash. Serious risks include pulmonary arterial hypertension (PAH), QT prolongation, bleeding complications, and severe cytopenias. Regular monitoring of complete blood counts (CBC), liver function tests, and cardiac function is necessary to mitigate treatment-related risks.